Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Kevin Shenk is active.

Publication


Featured researches published by Kevin Shenk.


Bioorganic & Medicinal Chemistry Letters | 2000

Methaqualone derivatives are potent noncompetitive AMPA receptor antagonists

Bertrand Leo Chenard; Frank S. Menniti; Martin J. Pagnozzi; Kevin Shenk; Frank E. Ewing; Willard Mckowan Welch

Quinazolin-4-one derivatives of methaqualone substituted at C-2 define a new class of noncompetitive antagonists at AMPA receptors.


Bioorganic & Medicinal Chemistry Letters | 1995

Synthesis of conformationally restricted substance P antagonists

Harry Ralph Howard; Kevin Shenk; Karen Coffman; Dianne K. Bryce; Rosemary T. Crawford; Stafford McLean

Reaction of CP-99,994 (1) with benzyl chloromethyl ether under basic conditions produced the novel 1,6-diazabicyclo[3.2.1]octane system in good yield; analogs containing this nucleus display high binding affinity for substance P receptors. The ethylene homologue of 1a, diamine 7, shows enhanced inhibitory activity and may more closely approximate the binding conformation of 1a at the NK1 receptor.


Archive | 1994

Diazabicyclic neurokinin antagonists

Harry Ralph Howard; Kevin Shenk


Bioorganic & Medicinal Chemistry Letters | 2004

CVT-4325: a potent fatty acid oxidation inhibitor with favorable oral bioavailability:

Elfatih Elzein; Prabha Ibrahim; Dmitry Koltun; Ken Rehder; Kevin Shenk; Timothy A. Marquart; Bob Jiang; Xiaofen Li; Reina Natero; Yuan Li; Marie Nguyen; Suresh Kerwar; Nancy Chu; Daniel Soohoo; Jia Hao; Victoria Y. Maydanik; David Lustig; Dewan Zeng; Kwan Leung; Jeff Zablocki


Bioorganic & Medicinal Chemistry Letters | 2004

New fatty acid oxidation inhibitors with increased potency lacking adverse metabolic and electrophysiological properties.

Dmitry Koltun; Timothy A. Marquart; Kevin Shenk; Elfatih Elzein; Yuan Li; Marie Nguyen; Suresh Kerwar; Dewan Zeng; Nancy Chu; Daniel Soohoo; Jia Hao; Victoria Y. Maydanik; David Lustig; Khing-Jow Ng; Heather Fraser; Jeffery A. Zablocki


Archive | 2001

Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors

Jeff Zablocki; Prabha Ibrahim; Kevin Shenk; Elfatih Elzein; Venkata Palle


Archive | 2003

Substituted piperazine compounds and their use as fatty acid oxidation inhibitors

Prabha Ibrahim; Kevin Shenk; Elfatih Elzein; Venkata Palle; Jeff Zablocki; Kenneth Rehder


Archive | 2002

Heteroaryl alkyl piperazine derivatives

Jeff Zablocki; Prabha Ibrahim; Kevin Shenk; Elfatih Elzein; Venkata Palle


Bioorganic & Medicinal Chemistry Letters | 2004

Structure-affinity relationships of 5'-aromatic ethers and 5'-aromatic sulfides as partial A1 adenosine agonists, potential supraventricular anti-arrhythmic agents

Christopher Morrison; Elfatih Elzein; Bob Jiang; Prabha Ibrahim; Timothy A. Marquart; Venkata Palle; Kevin Shenk; Vaibhav Varkhedkar; Tenning Maa; Lin Wu; Yuzhi Wu; Dewan Zeng; Irving Fong; David Lustig; Kwan Leung; Jeff Zablocki


Archive | 2003

Compounds dor increasing abca-1 expression useful for treating coronary artery disease and atherosclerosis

Prabha Ibrahim; Michael Campbell; Robert Jiang; Christopher Morrison; Kevin Shenk; William Shirley; Jeff Zablocki; Dmitry Koltun; Reina Natero

Collaboration


Dive into the Kevin Shenk's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Dewan Zeng

Virginia Commonwealth University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Suresh Kerwar

University of California

View shared research outputs
Researchain Logo
Decentralizing Knowledge